These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3456785)

  • 1. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.
    Mortensen SA; Olsen HS; Baandrup U
    Br Heart J; 1986 Mar; 55(3):274-82. PubMed ID: 3456785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
    Torti FM; Bristow MM; Lum BL; Carter SK; Howes AE; Aston DA; Brown BW; Hannigan JF; Meyers FJ; Mitchell EP
    Cancer Res; 1986 Jul; 46(7):3722-7. PubMed ID: 3458531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.
    Jones RL; Miles DW
    Lancet Oncol; 2005 Feb; 6(2):67. PubMed ID: 15683815
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy.
    Mackay B; Ewer MS; Carrasco CH; Benjamin RS
    Ultrastruct Pathol; 1994; 18(1-2):203-11. PubMed ID: 8191628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.
    Suzuki J; Yanagisawa A; Shigeyama T; Tsubota J; Yasumura T; Shimoyama K; Ishikawa K
    Angiology; 1999 Jan; 50(1):37-45. PubMed ID: 9924887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis.
    Fitter W; deSa DJ; Pai KR
    J Clin Pathol; 1981 Jun; 34(6):602-5. PubMed ID: 7251903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of tests for monitoring doxorubicin-induced cardiomyopathy.
    Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A
    Oncology; 1996; 53(6):461-70. PubMed ID: 8960141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-induced cardiotoxicity. An ultrastructural study.
    Shek TW; Luk IS; Ma L; Cheung KL
    Arch Pathol Lab Med; 1996 Jan; 120(1):89-91. PubMed ID: 8554453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endomyocardial biopsy.
    Laser JA; Fowles RE; Mason JW
    Cardiovasc Clin; 1985; 15(1):141-63. PubMed ID: 3916087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
    Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
    Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
    Okada Y; Horikawa K; Sano M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
    Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
    Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
    Torti FM; Bristow MR; Howes AE; Aston D; Stockdale FE; Carter SK; Kohler M; Brown BW; Billingham ME
    Ann Intern Med; 1983 Dec; 99(6):745-9. PubMed ID: 6651020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.
    Karagoz B; Suleymanoglu S; Uzun G; Bilgi O; Aydinoz S; Haholu A; Turken O; Onem Y; Kandemir EG
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):287-92. PubMed ID: 18248515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline cardiomyopathy monitored by morphologic changes.
    Billingham ME; Mason JW; Bristow MR; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):865-72. PubMed ID: 667860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
    Mortensen SA; Aabo K; Jonsson T; Baandrup U
    Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and prevention of doxorubicin cardiomyopathy.
    Ferrans VJ; Clark JR; Zhang J; Yu ZX; Herman EH
    Tsitologiia; 1997; 39(10):928-37. PubMed ID: 9505340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subacute anthracycline cardiotoxicity.
    Hengel CL; Russell PA; Gould PA; Kaye DM
    Heart Lung Circ; 2006 Feb; 15(1):59-61. PubMed ID: 16473794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.